Panacea Biotec wins UNICEF order worth ₹315 crore for bOPV supply

Vaccines maker Panacea Biotec Ltd on Friday (October 3) announced that it has received a Letter of Award from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of bivalent oral polio vaccine (bOPV).

The award is part of a Long-Term Agreement under which the company will supply bOPV in 10 and 20-vial presentations to UNICEF from April 1, 2026, to March 31, 2030. The total value of the award for Q2 CY2026 and CY2027 stands at approximately $35.65 million (around ₹315 crore).

Also Read: Panacea Biotec gets UNICEF order to supply 115 mn oral polio vaccines in 2025

According to the disclosure, the contract is international in nature and will be executed over Q2 CY2026 and CY2027. UNICEF will publicly publish details of the award on its website, including the supplier’s name, vaccines covered, duration of the award, total award value, and awarded prices per supplier per product presentation per year.

Panacea Biotec confirmed that neither its promoter, promoter group, nor group companies have any interest in UNICEF, the awarding entity, and the transaction does not fall within related party transactions. The order involves the supply of vaccines to UNICEF as per requirements received from time to time during the contract period.

Shares of Panacea Biotec Ltd ended at ₹415.00, up by ₹12.85, or 3.20%, on the BSE.

Also Read: Panacea Biotec not to pay 18% GST on leasehold land, says Bombay HCRead about our editorial guidelines and ethics policy